In August 2026, the U.S. Department of Veterans Affairs announced the launch of a new clinical trial to evaluate the effectiveness and safety of psilocybin to treat major depression in Veterans, including those with concurrent post-traumatic stress disorder.

Titled “Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression,” or PIVOT, the trial reflects VA’s commitment to pursuing innovative solutions for Veterans who have not responded to existing treatments. It will be conducted at five locations including the VA Puget Sound Health Care System where it will be led by Rebecca Hendrickson, MD, PhD.

The randomized, controlled trial will enroll Veterans diagnosed with treatment-resistant major depressive disorder, with or without concurrent PTSD, and will compare outcomes between two psilocybin dosage levels.

The health and safety of Veterans who choose to participate in this trial is VA’s top priority. The trial will be conducted in a safe, controlled, clinical setting using pharmaceutical-grade drugs under careful quality controls, stringent safety protocols that were developed with FDA, and in a setting that includes psychological support.